Navigation Links
Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Date:2/5/2009

WALTHAM, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the third quarter of fiscal year 2009, ended December 31, 2008. Total revenue for the quarter was $6,018,000 compared to $4,664,000 for the third quarter of fiscal year 2008. Total revenue was comprised of Protein A product revenue, and royalty and other revenue. Product revenue for the quarter was $3,294,000 and royalty and other revenue was $2,724,000, comprised primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia(R) (abatacept) and grant revenue from the Muscular Dystrophy Association.

Operating expenses for the third quarter of fiscal year 2009 were $6,556,000 compared to $5,663,000 for the same period in fiscal year 2008. This increase in operating expenses of $893,000 was primarily the result of increased spending associated with advancement of our Phase 3 clinical trial of RG1068 for pancreatic imaging, and initiation of our Phase 2b clinical trial of RG2417 for bipolar depression, as well as increased research and development expenses associated with our program to identify a clinical candidate for Friedreich's ataxia. These increases in spending were partially offset by reductions in legal and other selling, general and administrative expenses.

The net income for the quarter was $18,000 or $0.00 per diluted share, compared to a net loss for the same quarter of fiscal year 2008 of $242,000 or $0.01 per diluted share. Cash, cash equivalents and marketable securities as of December 31, 2008 were $64,509,000 compared to $60,589,000 as of March 31, 2008.

"We are pleased to have advanced our pipeline and achieved strong revenue growth during a quarter marked by continued global financial turmoil," stated Walter C. Herlihy, President and Chief Executive Officer of
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
3. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
4. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
5. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
6. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
7. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
10. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... Texas , May 30, 2015  Caris ... from a study in which researchers identified biomarker ... metachronous paired glioma tumors, indicating changes in response ... observing 19 patients was a subset of a ... molecular heterogeneity of the cancer. These data utilizing ...
(Date:5/29/2015)... , May 29, 2015 In recent years, ... availability of Big Data that can generate valuable insights. ... with utilizing Big Data have caused the biopharmaceutical sector ... industries. According to a recent study ... already have a Big Data team or function in ...
(Date:5/29/2015)... 29, 2015 GeneWEAVE, Inc ... (MDROs), announced that initial feasibility data supporting the ... and susceptibility testing from positive blood cultures will ... 31, 2015 in New Orleans, LA. The Company’s ... diagnostics that can quickly detect bacteria and assess ...
(Date:5/29/2015)... -- Asthma treatment could   see ... treatments enter arena, says   GBI Research ... several of the leading asthma brands, such as Advair ... the global market for asthma treatment is set to ...   New analysis from business intelligence provider ...
Breaking Biology Technology:Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3
... YORK, April 5, 2011 Sangamo BioSciences, ... Inc. have announced a collaboration to develop a novel ... zinc finger DNA-binding protein (ZFP) technology. The ZFP therapeutic ... an inherited neurodegenerative disease for which there are currently ...
... 2011 The European Commission (EC) has approved, under the ... DuPont Denmark Holding ApS to acquire all of the outstanding ... cash per share. DuPont Denmark Holding ApS is a wholly ... "We are pleased to have achieved one of the ...
... CHAMPAIGN, Ill. With the first observation of thermoelectric ... that graphene transistors have a nanoscale cooling effect that ... engineering professor William King and electrical and computer engineering ... in the April 3 advance online edition of the ...
Cached Biology Technology:Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntington's Disease 2Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntington's Disease 3Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntington's Disease 4European Commission Approves DuPont Tender Offer to Acquire Danisco 2European Commission Approves DuPont Tender Offer to Acquire Danisco 3Self-cooling observed in graphene electronics 2
(Date:5/25/2015)... SYDNEY , May 25, 2015  Australia,s market ... inception stage, although 2014 saw the advent of several ... on 24 April 2015 is expected to ignite interest ... devices in Australia . This in ... the industry and drive new partnerships amongst vendors and ...
(Date:5/21/2015)... , May 21, 2015 ... Imaging Market by Solutions (Hardware, Software, Services), by Applications ... & others), by End-Users (Military & Defense & ... MarketsandMarkets, Thermal Imaging Market is expected to grow ... by 2020, at a Compound Annual Growth Rate ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... due to predators, particularly in fragmented forest areas, but why? ... predator to find an answer. , "Rat snakes ... said U of I researcher Patrick Weatherhead. "Our hypothesis ... the edges of the forest, that,s where bird nests should ...
... being spewed into the Gulf of Mexico from the Deepwater ... the leak. However, in the cleanup efforts to come, "extreme ... bad situation even worse, says a leading bioremediation expert with ... of detergents and other chemicals used to clean up sites ...
... the University of Granada (UGR) have studied the natural history ... of Polygala balansae in Europe, a thorny bush ... previously thought to be exclusive to Morocco. The team of ... on the list of threatened species. In 2006, a ...
Cached Biology News:Fragmented forests result in more snakes, fewer birds 2Fragmented forests result in more snakes, fewer birds 3Caution required for Gulf oil spill clean-up 2Polygala balansae, a new bush to Europe, at risk of extinction in Spain 2
Request Info...
Human RUNX2/CBFA1 MAb (Clone 232902)...
Lipid-rich bovine serum albumin for cell culture (1). It is chromatographically purified and has an IgG content 0.1% (w/w)....
normal rat IgM AF647...
Biology Products: